FDA To Review Sanofi Weight Loss Pill
June 13, 2007
Experts from the FDA are scheduled to review the safety and efficacy of a weight loss pill named “Accomplia” that is approved for use in Eurpoe. The drug is made by Sanofi-Aventis, and if approved in the states, will be named Zimulti (Rimonabant).
The drug is a cannabinoid receptor antagonist and blocks the CB1 receptors in the brain that control hunger. Taking the drug reduces hunger and suppresses appetite. There is also promise that the drug may reduce the urge to smoke.
The pannel will weigh the drugs benifits versues it’s risks.
Benefits include that a dose of 20MG/day helped people to lose weight and reduce levels blood sugar, cholesterol, and fats.
However, in clinical trials there was an increased risk of suicide or suicidal thoughts in those who took the drug compared to patients who took the placebo.
The Manufacturer has emphasized that the drug is not for cosmetic purposes and is intented for those who are overweight or obese as part of a diet and exercise program.
For more detailed information on the drug’s assessment in Europe, see the European Public Assessment Report (PDF).
Comments
Got something to say?
Powered by WordPress
